MDT
Reimbursement: the unsexy growth lever
Medtronic said the American Medical Association approved new Category I CPT codes for two of its devices: Altaviva, an implantable tibial neuromodulation device for urge urinary incontinence, and Symplicity Spyral, its renal denervation system for uncontrolled hypertension.
If that sounds like alphabet soup, the investor takeaway is pretty simple: Category I codes are the good ones. They’re the signal that a technology has enough clinical evidence and physician adoption to move into more standard billing territory. In other words, less friction when doctors and hospitals try to get paid.
Why this matters
The new codes don’t kick in until January 2028, so this isn’t an instant revenue jolt. But it does improve the long-term commercialization picture for two therapies Medtronic has been trying to turn into real businesses, not just nice slides in an investor deck.
That matters because in medtech, reimbursement can be half the battle. A device can be clinically compelling and still struggle if the billing setup feels like a bureaucratic escape room. Better codes help remove that roadblock.
The bigger picture
Medtronic keeps stacking small wins that point to a more mature growth story beyond its legacy franchises. Today it’s coding approvals; tomorrow it’s whether hospitals and doctors actually lean in.
Big picture: this is more of a slow-burn positive than a fireworks moment, but in healthcare tech, those boring regulatory breadcrumbs can eventually turn into very real money.